Ventricular Assist Device Implantation

Quick Answer

Ventricular assist device (VAD) implantation is a major cardiac surgical procedure for patients with end-stage heart failure. The three configurations are: (1) Left VAD (LVAD) - most common (80%), blood inflow from left ventricle apex, outflow to ascending aorta; (2) Right VAD (RVAD) - inflow from right atrium, outflow to pulmonary artery, often temporary; and (3) Biventricular VAD (BiVAD) - both ventricles supported, highest risk. Critical anaesthetic considerations include: (1) Preoperative optimization of right ventricular (RV) function (30-50% develop RV failure post-LVAD); (2) Meticulous anticoagulation management (therapeutic heparin with ACT >400s on CPB); (3) Deairing procedures (patient in steep Trendelenburg, Valsalva manoeuvres); (4) Inotropic support for RV (milrinone, dobutamine, inhaled NO); (5) Hemodynamic goals with non-pulsatile flow (MAP 70-80 mmHg, adequate preload). Modern centrifugal flow pumps (HeartMate 3, HVAD) have largely replaced pulsatile devices.[1-5]

---

Overview

Ventricular assist devices (VADs) represent a transformative therapy for patients with end-stage heart failure, providing mechanical circulatory support as either a bridge to transplantation (BTT), bridge to recovery (BTR), destination therapy (DT), or bridge to candidacy (BTC).[1] The field has evolved dramatically since the first clinical VAD implantation in 1966, with contemporary continuous-flow centrifugal and axial pumps offering improved durability, reduced complications, and enhanced quality of life compared to earlier pulsatile devices.[2]

The most common configuration is the left ventricular assist device (LVAD), which unloads the failing left ventricle and provides systemic perfusion, allowing the native heart to rest and potentially recover.[3] However, the procedure presents formidable anaesthetic challenges: patients often have multi-organ dysfunction preoperatively, the surgery involves prolonged cardiopulmonary bypass (CPB), and the transition to non-pulsatile flow creates unique hemodynamic considerations.[4]

Right ventricular failure following LVAD implantation remains the Achilles' heel of this therapy, occurring in 30-50% of patients and significantly increasing morbidity and mortality.[5] The mechanism involves RV septal shift toward the left with increased septal contribution to RV contractility, altered RV geometry from LV decompression, and increased RV preload while maintaining or increased RV afterload.[6] Recognition and management of RV dysfunction requires vigilance and often additional mechanical support.

Modern device technology has shifted almost exclusively to continuous-flow pumps. The HeartMate 3 (Abbott) and HVAD (Medtronic, now largely replaced) use fully magnetically levitated centrifugal rotors, eliminating mechanical bearings and reducing thrombosis risk.[7] These devices operate at 3,000-6,000 rpm, generating flows of 3.0-6.0 L/min depending on preload and afterload conditions.[8]

Australian and New Zealand practice follows international trends but with specific considerations for geographic isolation. The limited availability of donor hearts makes destination therapy increasingly important, while the need for complex post-VAD management necessitates coordination between tertiary implanting centres and regional hospitals.[9] Indigenous populations face additional barriers to VAD therapy access, requiring culturally appropriate approaches to patient selection and postoperative support.[10]

---

Device Classification and Technology

Device Configurations

Left Ventricular Assist Device (LVAD):

• Indications: Isolated LV failure with preserved RV function
• Configuration: Inflow cannula from LV apex; outflow graft to ascending aorta
• Flow characteristics: Continuous non-pulsatile flow; 3.0-6.0 L/min typical
• Preload dependence: Flow varies with LV filling (Frank-Starling physiology preserved inversely)[1]
• Afterload dependence: Pump output inversely related to systemic vascular resistance (SVR)
• Pulsatility: Native LV contributes residual pulsatility; "pulse pressure" often 10-20 mmHg

Right Ventricular Assist Device (RVAD):

• Indications: RV failure post-LVAD, isolated RV failure, postcardiotomy shock
• Configuration: Inflow from right atrium; outflow to pulmonary artery
• Temporary vs durable: Usually temporary (CentriMag, Protek Duo) for post-LVAD RV failure; occasionally durable (Berlin Heart EXCOR, HeartWare RVAD)[2]
• Flow target: 3.0-5.0 L/min to match LVAD output
• Monitoring: CVP target 5-10 mmHg; avoid excessive preload

Biventricular Assist Device (BiVAD):

• Indications: Biventricular failure, severe RV failure post-LVAD not responsive to medical therapy
• Configuration: Separate LVAD and RVAD systems
• Flow balancing: RVAD output must equal LVAD output to prevent pulmonary congestion or LV underfilling
• Prognosis: Bridge to transplant in >90% (highest priority on transplant list); poor outcomes if transplant unavailable[3]

Total Artificial Heart (TAH):

• Devices: SynCardia temporary TAH, CARMAT bioprosthetic TAH (limited availability)
• Indications: Biventricular failure with irreparable valves, ventricular septal defect, severe arrhythmias unsuitable for VADs
• Limitations: Large device size, requires bilateral pneumonectomy space, complexity

Pump Technology Generations

First Generation: Pulsatile Flow (Historical)

• HeartMate XVE, Novacor, Thoratec PVAD
• Pneumatic or electromechanical pusher-plate technology
• Large size, limited durability (18-24 months), high thrombosis risk
• Now rarely used except in specific scenarios

Second Generation: Continuous-Flow Axial[4]

• HeartMate II (Thoratec/Abbott)
• Axial flow impeller with mechanical bearings
• Smaller than pulsatile devices; better durability
• 8,000-10,000 rpm operating range
• Bearing wear and thrombosis risk led to gradual replacement by third-generation devices

Third Generation: Continuous-Flow Centrifugal with Magnetic Levitation[5]

• HeartMate 3 (Abbott): Currently the most implanted durable LVAD globally

  • Fully magnetically levitated rotor eliminates mechanical wear
  • Artificial pulse algorithm (intermittent speed reduction) to enhance washout
  • Wide operational speed range (3,000-6,000 rpm)
  • Flow range 2.5-10 L/min
  • Lower thrombosis rates than axial flow pumps

• HVAD (Medtronic): Centrifugal device with hybrid mag-lev and hydrodynamic bearings

  • Smaller implantable pump profile (intrathoracic)
  • 2,400-3,200 rpm operating range
  • 10-year outcomes established
  • Some markets transitioning to HeartMate 3 exclusively

• Jarvik 2000: Axial flow pump with intraventricular placement

  • Unique "cross-beams" fixation within LV cavity
  • Operates at 8,000-12,000 rpm
  • Small driveline profile

Pump Physiology and Hemodynamics

Flow Dynamics:[6]

• Centrifugal pumps generate flow based on impeller rotation speed and pressure differential
• Flow (Q) = k × (RPM × Viscosity) / (Afterload - Preload)
• Preload dependence: As LV fills, pump output increases (up to maximum capacity)
• Afterload sensitivity: Increased SVR reduces pump output at constant RPM
• Viscosity effects: Higher hematocrit increases resistance and reduces flow slightly

Pressure-Volume Relationships:

• Mean arterial pressure (MAP): Target 70-80 mmHg (avoid >90 mmHg which increases afterload)
• Central venous pressure (CVP): Target 5-12 mmHg (reflects RV function)
• Pulmonary artery pressure (PAP): Monitor for RV failure; ideally <30/15 mmHg
• Pump power consumption: Reflects afterload and potential thrombosis (sudden increase = alarm)

Native Heart Contribution:

• With continuous-flow LVAD, native LV unloads and contracts minimally
• Residual aortic valve opening occurs with preserved LV contractility or intermittent speed reductions
• Aortic valve typically remains closed 60-80% of time in continuous-flow mode
• Risk of aortic valve fusion and insufficiency with long-term support (>1 year)[7]

---

Preoperative Assessment

Patient Selection Criteria

The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria guide patient selection:[8]

INTERMACS Profiles (Indication Severity):

Indications for LVAD Implantation:

• Bridge to Transplant (BTT): Temporary support until transplant; 40-50% of implants
• Destination Therapy (DT): Permanent support for non-transplant candidates; 40-50% of implants
• Bridge to Recovery (BTR): Temporary support for potentially reversible cardiomyopathy (<5%)
• Bridge to Candidacy (BTC): Support while addressing contraindications to transplant (obesity, renal dysfunction, pulmonary hypertension)[9]

Absolute Contraindications:

• Irreversible renal dysfunction (eGFR <30 without dialysis plan)
• Fixed pulmonary hypertension (PVR >6 Woods units unresponsive to vasodilators)
• Active systemic infection or sepsis
• Uncorrected severe aortic regurgitation (requires valve repair/replacement)
• Severe coagulopathy or contraindication to anticoagulation
• Neurological dysfunction limiting self-care or VAD management
• Severe frailty or limited social support for post-discharge care

Relative Contraindications:

• Advanced age (>75-80 years for DT)
• Morbid obesity (BMI >35-40)
• Diabetes with end-organ damage
• Peripheral vascular disease limiting mobility
• Psychological instability or non-compliance history

Preoperative Risk Stratification

Risk Scores:

• HMRS (HeartMate Risk Score): Predicts 90-day mortality; includes age, albumin, creatinine, INR, center volume[10]
• MELD Score: Liver dysfunction predicts post-VAD mortality
• CRIT Score: RV failure prediction (CVP/PCWP ratio >0.63, RVSWI <300, female sex, preoperative IABP)[11]

Right Ventricular Function Assessment:

Critical to predict post-LVAD RV failure:[12]

Investigations Required:

Cardiac:

• Transthoracic echocardiography: LV/RV function, valvular disease, septal position
• Right heart catheterization: PA pressures, PVR, cardiac output, RVSWI
• Coronary angiography: CAD assessment if not recently performed
• CT chest/abdomen: Aortic atherosclerosis, intracardiac thrombus, anatomical suitability

Pulmonary:

• Pulmonary function tests: Severe COPD contraindication
• ABG: Baseline oxygenation, hypercarbia assessment

Renal/Metabolic:

• eGFR, creatinine, BUN
• Liver function: LFTs, coagulation profile
• Electrolytes: Potassium, magnesium critical for arrhythmia prevention

Hematological:

• CBC: Anemia requiring preoperative transfusion
• Coagulation: INR, aPTT, platelet function
• HLA antibody screen (for BTT patients)

Infectious:

• Blood cultures if febrile
• MRSA/MSSA screening
• Dental evaluation (infection risk)
• Hepatitis/HIV serology

Preoperative Optimization

Cardiovascular:

• Inotropes: Milrinone (0.375-0.75 mcg/kg/min), dobutamine (5-10 mcg/kg/min) for INTERMACS 2-3
• IABP: Consider for INTERMACS 1-2 to reduce afterload, improve coronary perfusion
• Mechanical ventilation: If respiratory failure from pulmonary edema
• Arrhythmia management: Amiodarone for atrial fibrillation; avoid class I agents (proarrhythmic)

Renal:

• Diuretics: Optimize volume status (furosemide, metolazone)
• Ultrafiltration/CVVH: If diuretic-resistant volume overload
• Dialysis: Initiate if uremic or refractory metabolic abnormalities

Nutritional:

• Albumin >30 g/L (higher mortality if <30)
• Prealbumin monitoring
• Enteral nutrition preferred; TPN if contraindicated

Anticoagulation Management:[13]

• Warfarin: Bridge with unfractionated heparin if INR therapeutic; stop 5-7 days preoperatively
• Aspirin: Continue through surgery (81-100 mg daily)
• DOACs: Stop per manufacturer guidelines (typically 48 hours)
• Heparin infusion: Continue until 4-6 hours preoperatively (aPTT <80 seconds acceptable for surgery)

---

Anaesthetic Management

Induction and Pre-CPB Phase

Induction Strategy:[14]

• Monitoring: Arterial line (pre-induction if cardiogenic shock), central venous catheter, pulmonary artery catheter (or advanced monitor like FloTrac/Vigileo)
• TEE probe: Insert after induction for continuous cardiac monitoring
• Induction agents: Etomidate (0.2-0.3 mg/kg) preferred for hemodynamic stability; avoid propofol if hypotensive
• Muscle relaxants: Rocuronium (0.6-1.0 mg/kg) or vecuronium; avoid pancuronium (tachycardia)
• Analgesia: High-dose opioid technique (fentanyl 10-20 mcg/kg or sufentanil 2-3 mcg/kg) to blunt sympathetic response

Maintenance:

• Balanced anaesthesia with sevoflurane (0.5-1.0 MAC) or desflurane
• TIVA alternative: Propofol (100-150 mcg/kg/min) + remifentanil (0.1-0.2 mcg/kg/min)
• BIS monitoring (40-60) for awareness prevention
• Temperature monitoring: Nasopharyngeal, bladder, and myocardial temperatures

Pre-CPB Hemodynamic Goals:

• MAP >65 mmHg (maintain cerebral/organ perfusion)
• CVP optimization (diuresis if >15 mmHg)
• Avoidance of tachycardia (maintain HR 60-80 bpm to reduce myocardial oxygen demand)
• Maintain coronary perfusion pressure

RV Function Optimization:[15]

• Inotropes: Milrinone 0.5 mcg/kg/min (loading 25-50 mcg/kg over 10 min if time permits), dobutamine 5-10 mcg/kg/min
• Vasopressors: Norepinephrine 0.05-0.2 mcg/kg/min (if vasoplegia from milrinone)
• Pulmonary vasodilators:
  • Inhaled nitric oxide (iNO) 10-40 ppm (if available)
  • Epoprostenol 0.5-2.0 ng/kg/min IV
  • Sildenafil 20 mg TID (enteral if not NPO)
• Ventilation: Avoid hypercarbia, hypoxia, acidosis (all increase PVR)

Cardiopulmonary Bypass Considerations

Cannulation Strategy:[16]

• Arterial: Aortic cannulation with wire-reinforced high-flow cannula (21-23 Fr)
• Venous: Bicaval cannulation with caval snares (interatrial septum may be opened for inflow cannula placement)
• Temperature: Mild hypothermia (28-32°C) or normothermic (35-37°C) depending on surgeon preference
• Flow rates: 2.0-2.5 L/min/m² (higher flows may be needed if aortic insufficiency)
• Anticoagulation: Unfractionated heparin 300-400 units/kg; target ACT >400-480 seconds

Pump Implantation Sequence:

1. Core cooling: If hypothermic CPB used
2. LV apex exposure: Diaphragmatic mobilization, pericardial traction sutures
3. Sewing ring placement: 2-0 or 3-0 braided sutures with pledgets at LV apex
4. Coring: Core removed from LV apex; inspect for trabeculations/thrombus
5. Inflow cannula insertion: Pump connected to sewing ring
6. Outflow graft anastomosis: 8-10 mm Dacron graft to ascending aorta (partial occlusion clamp or full CPB)
7. Tunneling: Driveline tunneled subcutaneously to exit site (right upper quadrant typically)
8. Deairing: Critical step before pump activation

Deairing Procedures (Critical Safety Step):[17]

Critical considerations:

• Air embolism with non-pulsatile flow can be catastrophic (cerebral, coronary, systemic)
• Even small air bubbles can obstruct coronary ostia with continuous flow
• Multiple TEE views (mid-esophageal aortic valve short-axis, 4-chamber) to confirm air clearance
• Maintain steep Trendelenburg for 5-10 minutes after pump initiation

Pump Initiation and Weaning from CPB

Pump Priming and Start-Up:[18]

• Power-up: Gradual increase from 1,000-2,000 rpm to target 4,000-6,000 rpm
• Flow targets: Initially 2.0-2.5 L/min; increase to 3.5-4.5 L/min as tolerated
• Power consumption: Typically 3-6 watts at normal flows; sudden increase suggests thrombosis
• Speed adjustments: Increase if low flow; decrease if suction events (intermittent alarms)

Hemodynamic Parameters with Non-Pulsatile Flow:[19]

Weaning from CPB:[20]

1. Rewarm to 37°C if hypothermic
2. Ensure deairing complete with TEE
3. Gradually reduce CPB flow while increasing LVAD support
4. Maintain LV preload to prevent suction events (CVP >8-10 mmHg)
5. Inotropic support ready: Milrinone, dobutamine, adrenaline
6. Vasopressors if needed: Norepinephrine (avoid excessive afterload)
7. Close monitoring for RV failure (rising CVP, falling BP)

Suction Events:[21]

• Mechanism: Excessive pump speed or inadequate LV preload causes inflow cannula occlusion against myocardium or septum
• Manifestation: Acute flow drop, arrhythmias (VT/VF), "chatter" on flow waveform
• Management: (1) Reduce pump speed by 200-400 rpm, (2) Increase preload (fluid bolus), (3) Adjust patient position, (4) Consider inotropes to improve LV filling

Arrhythmia Management:

• Ventricular fibrillation: Can be tolerated with full LVAD support; deliver asynchronous energy if prolonged
• Ventricular tachycardia: Amiodarone 150 mg IV, lidocaine 1 mg/kg; cardioversion if hemodynamically significant
• Atrial fibrillation: May reduce pump preload; rate control with amiodarone, magnesium; cardioversion if flow compromised

---

Postoperative Management

Immediate Post-CPB Care (ICU)

Monitoring:[22]

• Device parameters: Continuous monitoring of pump speed (rpm), flow (L/min), power (watts), pulsatility index
• Hemodynamics: Arterial line, CVP, PA pressures if catheter in situ
• TEE: Postoperative assessment of RV function, inflow/outflow cannula position, deairing
• ECG: Continuous monitoring for arrhythmias
• Temperature: Normothermia (36.5-37.5°C)
• Urine output: >0.5 mL/kg/hour

Anticoagulation Protocol:[23]

• Immediate postoperative: Heparin infusion started 12-24 hours postoperatively once mediastinal bleeding controlled (<50 mL/hour for 2 consecutive hours)
• Heparin targets:
  • aPTT 45-60 seconds (if monitoring anti-Xa: 0.3-0.5 IU/mL)
  • Bridge to warfarin once enteral feeding established
• Warfarin initiation: Day 2-3 postoperatively
  • Target INR 2.0-3.0 (2.5-3.5 if history of thrombosis)
  • Bridge with heparin until INR therapeutic for 2 consecutive days
• Aspirin: 81-100 mg daily started Day 1 postoperatively
• Duration: Lifelong anticoagulation required

Hemodynamic Goals:[24]

Inotropic Support:[25]

• RV support: Milrinone 0.5 mcg/kg/min ± dobutamine 5-10 mcg/kg/min
• Vasopressors: Norepinephrine 0.05-0.5 mcg/kg/min (titrate to MAP 70-80)
• Vasodilators: Nitroprusside 0.5-5.0 mcg/kg/min if SVR >1,200 dyn·s/cm⁵
• Inhaled NO: 10-40 ppm if RV dysfunction with elevated PVR
• Weaning: Gradual reduction over 48-96 hours as RV function stabilizes

Right Ventricular Failure Management

Incidence: 30-50% post-LVAD; 5-10% require mechanical RV support[26]

Risk Factors:

• Preoperative RV dysfunction (TAPSE <8 mm, RVFAC <25%)
• Female sex
• Non-ischemic cardiomyopathy
• Preoperative IABP or inotrope dependence
• Elevated CVP/PCWP ratio >0.63
• Intraoperative arrhythmias

Clinical Recognition:[27]

Medical Management:[28]

• Optimize LVAD settings: Reduce speed to 3,000-4,000 rpm to maintain some LV volume and septal position
• Inotropes: Milrinone 0.5-0.75 mcg/kg/min, dobutamine 5-10 mcg/kg/min, isoproterenol 0.01-0.1 mcg/kg/min
• Vasopressors: Norepinephrine to maintain MAP and RV coronary perfusion
• Pulmonary vasodilators: iNO 10-40 ppm, sildenafil, epoprostenol
• Fluid management: Maintain CVP 10-15 mmHg (higher than normal to ensure RV preload)

Mechanical RV Support (RVAD):[29]

• Indications: Refractory RV failure despite maximum medical therapy; CVP >20 mmHg with falling cardiac output
• Devices:
  • CentriMag (centrifugal pump) most common
  • Protek Duo (dual-lumen cannula, less invasive)
  • Impella RP (axial flow, limited availability)
  • TandemHeart RA-PA (percutaneous)
• Configuration: Inflow from right atrium; outflow to pulmonary artery
• Flow target: Match LVAD output (3.0-5.0 L/min)
• Balancing: Critical to avoid pulmonary edema (too much flow) or LV underfilling (too little)
• Weaning: Attempt after 7-14 days as RV recovers; 60-70% can be weaned

Common Complications

Bleeding and Coagulopathy:[30]

• Incidence: 40-60% require blood transfusion; 10-15% require re-exploration
• Etiology:
  • Preoperative coagulopathy (liver dysfunction, malnutrition)
  • CPB-induced platelet dysfunction and coagulopathy
  • Anticoagulation (heparin, warfarin)
  • Device-related acquired von Willebrand disease (AVWS)
• Management:
  • Blood products per massive transfusion protocol: PRBC, FFP, platelets, cryoprecipitate
  • Factor concentrates: Fibrinogen concentrate, PCC (prothrombin complex concentrate)
  • TXA 1-2 g IV
  • Recombinant Factor VIIa (last resort, increases thrombosis risk)
  • DDAVP 0.3 mcg/kg (improves platelet function)

Pump Thrombosis:[31]

• Incidence: 5-10% with HeartMate 3 (lower than axial pumps); higher with inadequate anticoagulation
• Warning signs:
  • Power consumption suddenly increases >2-3 watts from baseline
  • Hemolysis: LDH >2.5x upper limit normal, plasma-free hemoglobin >20 mg/dL, haptoglobin <10 mg/dL
  • Low flow despite adequate preload and afterload
  • Chest pain, fatigue, new symptoms
• Diagnosis:
  • TTE/TEE: Visualize inflow cannula for thrombus
  • CT chest: Assess pump and cannulas
  • Laboratory: Falling hemoglobin, elevated LDH, hemoglobinuria
• Management:
  • Anticoagulation optimization: Ensure therapeutic INR, therapeutic heparin
  • Fibrinolysis: tPA or tenecteplase (controversial, risk of bleeding)
  • Pump exchange: Surgical replacement if thrombosis refractory (high mortality)
  • Transplant: Expedited if BTT patient

Device Infection:[32]

• Types:
  • Pocket infection (drive-line exit site): Most common
  • Pump/cannula infection: Rare but serious
  • Sepsis/bacteremia: From driveline colonization
• Organisms: Staphylococcus aureus, coagulase-negative staphylococci, Pseudomonas, fungi
• Prevention:
  • Meticulous driveline care: Daily cleaning with chlorhexidine, sterile dressing
  • Immobilization: Driveline stabilization to prevent traction
  • Antibiotic prophylaxis: Perioperative and dental procedures
• Management:
  • Broad-spectrum antibiotics tailored to culture results
  • Drive-line infection: May be managed with antibiotics + local care
  • Deep infection/pump infection: May require device exchange or transplant

Neurological Complications:[33]

• Stroke: 8-15% incidence; higher with inadequate anticoagulation or hypertension
  • Ischemic: Most common; related to thrombus or air embolism
  • Hemorrhagic: Related to anticoagulation, hypertension
• Management:
  • CT brain immediately if neurological deficit
  • Thrombolysis generally contraindicated (anticoagulation, bleeding risk)
  • Blood pressure control: Avoid hypotension; treat hypertension
• Cognitive dysfunction: Delirium common postoperatively; multifactorial

Aortic Insufficiency:[34]

• Mechanism: Chronic closure of aortic valve leads to leaflet fusion and insufficiency
• Incidence: 20-30% at 2 years; 50-70% at 4 years with continuous-flow pumps
• Impact: Recirculation reduces systemic flow; worsens LV dilation
• Management:
  • Aortic valve replacement or repair if moderate-severe
  • Transcatheter aortic valve replacement (TAVR) in selected patients
  • Increase pump speed to close aortic valve (temporary measure)

Other Complications:

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples in Australia experience cardiovascular disease at rates 2-3 times higher than non-Indigenous populations, with heart failure representing a significant and growing burden.[35] However, access to advanced heart failure therapies including VADs remains limited for Indigenous patients due to geographical, socioeconomic, and systemic barriers.

Epidemiological Context: Indigenous Australians develop heart failure at younger ages (mean age 55-60 years vs 70+ for non-Indigenous) due to higher rates of rheumatic heart disease, ischemic heart disease, diabetes, and renal disease. The prevalence of risk factors including smoking (40-50% vs 12-15%), obesity (40-50% vs 25-30%), and hypertension creates a population with significant unmet need for mechanical circulatory support.[36] Despite this, VAD implantation rates in Indigenous populations are disproportionately low, reflecting access barriers rather than lower clinical need.

Cultural and Communication Considerations: Consent for VAD implantation requires understanding complex technology, lifelong lifestyle modifications, and dependence on electrical power and anticoagulation. For Aboriginal and Torres Strait Islander patients, particularly those from remote communities with limited English proficiency, informed consent processes must be culturally adapted. Visual aids, video education in local languages, and involvement of Aboriginal Health Workers are essential. Extended family decision-making may require additional time, which can be challenging when patients present in cardiogenic shock (INTERMACS 1-2).[37]

Geographical and System Barriers: VAD implantation occurs only in major metropolitan cardiac surgery centres (Sydney, Melbourne, Brisbane). Indigenous patients from remote and regional areas must travel long distances, often without family support, for assessment, implantation, and postoperative care. The Patient Assisted Travel Scheme (PATS) provides limited assistance, and family members who play crucial roles in decision-making and recovery may be unable to accompany patients due to cost and cultural obligations.[38]

Post-discharge VAD management requires regular follow-up at implanting centres or accredited spoke sites, typically monthly initially then quarterly. For Indigenous patients from remote areas, this presents insurmountable barriers. Some patients relocate temporarily to metropolitan areas, disrupting family and community connections. The "post-discharge cliff" phenomenon—loss to follow-up after cardiac surgery—is particularly pronounced in Indigenous populations.[39]

Health System Considerations: The Closing the Gap initiative has improved cardiovascular care access, but VAD therapy remains largely inaccessible to remote Indigenous populations. Telemedicine and remote monitoring technologies offer potential solutions, allowing device parameters to be monitored from remote clinics. However, infrastructure limitations (internet connectivity, power reliability) and the need for emergency response capabilities limit widespread implementation. Mobile VAD support teams and partnerships between metropolitan implanting centres and regional hospitals are being developed to improve access.[40]

Driveline and Cultural Practices: Traditional cultural practices including ceremonial dancing and physical activities may pose risks to driveline integrity. Patient education must address these specific concerns, and driveline immobilization strategies must account for active lifestyles. Bathing in natural water sources (creeks, billabongs) increases infection risk and requires alternative hygiene education that respects cultural practices while ensuring driveline safety.[41]

Māori Health

Māori populations in New Zealand experience similar disparities in cardiovascular disease and heart failure, with age-standardised rates 1.5-2 times higher than non-Māori populations. The principles of Te Tiriti o Waitangi guide health service delivery, requiring equitable access to advanced therapies and culturally appropriate care pathways.[42]

Whānau and Decision-Making: Māori health decision-making involves collective whānau processes that may conflict with urgent clinical timelines. For patients presenting in cardiogenic shock requiring emergent VAD implantation, there may be insufficient time for full whānau consultation. Healthcare teams must balance respect for cultural decision-making with the life-saving urgency of mechanical support. Advance care planning and culturally appropriate education about VAD therapy should occur earlier in the heart failure trajectory for Māori patients.[43]

Cultural Safety and Institutional Racism: Māori patients may experience institutional racism within healthcare settings, contributing to delayed presentation and reluctance to engage with complex therapies like VADs. Creating culturally safe environments requires not only individual provider attitudes but systemic changes including Māori workforce development, kaupapa Māori service models, and Whānau Ora approaches that address broader social determinants of health alongside clinical interventions.[44]

Rural and Regional Access: New Zealand's geography creates access challenges for Māori living in rural areas. VAD implantation occurs in Auckland, Wellington, Christchurch, and Dunedin. Travel costs, accommodation, and disruption to whānau and employment create significant barriers. The development of spoke sites for post-VAD follow-up in regional centres with telemedicine support to implanting centres improves access, but challenges remain for the most remote communities.[45]

Postoperative Support: VAD management requires lifelong anticoagulation with warfarin, regular INR monitoring, and medication adherence. For Māori patients, understanding of tikanga (customs) and the impact of dietary variations (traditional foods may be vitamin K-rich) on anticoagulation is important. Community-based care coordination through Māori health providers improves medication adherence and follow-up engagement.[46]

Health Equity Initiatives: The 2022 New Zealand health reforms established Te Aka Whai Ora (Māori Health Authority) with specific responsibilities for improving cardiovascular outcomes for Māori. This includes targeted programmes for heart failure prevention, earlier referral for advanced therapies, and culturally appropriate VAD pathways. For anaesthetists and cardiac surgeons, this means proactive engagement with Māori patients and whānau, cultural safety training, and advocacy for equitable resource allocation.[47]

---

ANZCA Examination Focus

Final Written Examination

High-Yield Topics:

1. Device types: LVAD vs RVAD vs BiVAD configurations; HeartMate 3 vs HVAD technology
2. Pump physiology: Preload and afterload dependence; non-pulsatile flow hemodynamics
3. RV failure prediction: Risk factors (CVP/PCWP ratio, RVSWI, female sex); prevention and management
4. Anticoagulation: Heparin bridging, warfarin target INR, antiplatelet therapy
5. Deairing: Critical steps (Trendelenburg, Valsalva, TEE); air embolism risk with non-pulsatile flow
6. Complications: Bleeding (AVWS), thrombosis (LDH, hemolysis), infection, neurological events
7. Hemodynamic goals: MAP 70-80 mmHg, CVP 5-12 mmHg, pump flow 3.5-5.5 L/min

Common SAQ Themes:

• Describe the perioperative management of a patient undergoing LVAD implantation as destination therapy
• A patient develops severe RV failure 6 hours post-LVAD implantation. Outline your management
• Discuss the anticoagulation protocol for a patient with a HeartMate 3 device
• Outline the approach to deairing during VAD implantation and the consequences of air embolism

Final Viva Voce

Viva Scenario 1: LVAD Overview

Examiner: "Tell me about left ventricular assist devices and their role in managing end-stage heart failure."

Candidate Response Framework:

1. Definition: Mechanical pump that unloads the failing left ventricle and provides systemic perfusion
2. Indications: Bridge to transplant (40%), destination therapy (40%), bridge to recovery/candidacy (20%)
3. Technology: Continuous-flow centrifugal pumps (HeartMate 3) with magnetically levitated rotors; 3.0-6.0 L/min flow
4. Configuration: Inflow cannula from LV apex, outflow graft to ascending aorta, driveline to external controller
5. Physiology: Non-pulsatile flow; preload-dependent; afterload-sensitive; MAP target 70-80 mmHg
6. Complications: RV failure (30-50%), bleeding, thrombosis, infection, stroke, aortic insufficiency

Viva Scenario 2: RV Failure Management

Examiner: "You are managing a patient in ICU 4 hours post-LVAD implantation. The CVP is rising (18 mmHg), MAP is falling (62 mmHg), and urine output has decreased. What is your approach?"

Candidate: "This presentation is consistent with right ventricular failure following LVAD implantation, which occurs in 30-50% of patients. The rising CVP reflects failing RV output, which inadequately fills the LV and reduces pump flow and systemic pressure.

My immediate approach would be:

First, confirm the diagnosis with bedside TEE looking for RV dilation, reduced TAPSE, and septal position. Check that the LVAD is functioning properly—flow should be 3.5-5.5 L/min with power consumption 3-6 watts.

Second, optimize the LVAD settings. I would reduce the pump speed to 3,000-4,000 rpm to maintain some LV volume, which improves septal position and RV geometry. Excessive decompression worsens RV function.

Third, optimize RV preload and afterload. Ensure adequate volume status (CVP 10-15 mmHg—not too high to cause congestion, not too low to underfill). Start inhaled nitric oxide at 20-40 ppm to reduce PVR, or IV epoprostenol if iNO not available.

Fourth, initiate inotropic support. Milrinone 0.5 mcg/kg/min provides both inotropy and pulmonary vasodilation. Add dobutamine 5-10 mcg/kg/min if additional inotropy needed. Norepinephrine 0.05-0.2 mcg/kg/min maintains MAP and RV coronary perfusion.

Fifth, if medical therapy fails and CVP >20 with continued deterioration, I would escalate to mechanical RV support with a CentriMag RVAD or Protek Duo, with inflow from right atrium and outflow to pulmonary artery.

Finally, ensure adequate anticoagulation once bleeding controlled, and consider temporary closure of ASD if present."

Viva Scenario 3: Anticoagulation

Examiner: "How would you manage anticoagulation for a patient undergoing LVAD implantation?"

Candidate: "Anticoagulation management for VAD patients has three phases: perioperative, immediate postoperative, and long-term maintenance.

Perioperatively, patients are typically on warfarin preoperatively for underlying heart failure or arrhythmias. I would stop warfarin 5-7 days before surgery and bridge with unfractionated heparin, which is stopped 4-6 hours preoperatively with target aPTT <80 seconds. Aspirin 81-100 mg is continued through the perioperative period.

During surgery, unfractionated heparin is administered after venous cannulation with a target ACT >400-480 seconds for cardiopulmonary bypass. This is higher than standard CPB to account for device thrombosis risk.

Postoperatively, I delay heparin initiation until mediastinal bleeding is controlled—typically 12-24 hours when drainage is <50 mL/hour for 2 consecutive hours. I use unfractionated heparin rather than LMWH to allow rapid reversibility if bleeding occurs. Target aPTT is 45-60 seconds or anti-Xa 0.3-0.5 IU/mL.

Warfarin is initiated on postoperative day 2-3 once enteral feeding is established. The target INR is 2.0-3.0, or 2.5-3.5 if the patient has a history of thrombosis. I bridge with heparin until INR is therapeutic for 2 consecutive days, then discontinue heparin.

Aspirin 81-100 mg daily is started on postoperative day 1 and continued lifelong. This dual antithrombotic therapy (warfarin + aspirin) is essential given the risk of pump thrombosis.

Importantly, the patient requires lifelong anticoagulation; interruption is only acceptable for life-threatening bleeding or emergency surgery with bridging protocols."

Common Mistakes in Examinations

Knowledge Errors:

• Not knowing pump physiology (preload-dependent, afterload-sensitive)
• Incorrect MAP target (should be 70-80 mmHg, not "normal" 90-100)
• Forgetting to mention RV failure prediction and management
• Not knowing deairing procedures (Trendelenburg, Valsalva)
• Incorrect anticoagulation targets (INR 2.0-3.0, not higher ranges)
• Confusing axial vs centrifugal pump technology

Clinical Reasoning Errors:

• Treating hypertension post-LVAD with aggressive vasodilators (may reduce pump flow)
• Not recognizing suction events (low flow with arrhythmias)
• Failing to optimize RV before LVAD implantation (check CVP/PCWP ratio, TAPSE)
• Stopping anticoagulation for minor bleeding (increases thrombosis risk)
• Not monitoring for hemolysis (LDH, plasma-free hemoglobin) as sign of thrombosis

---

Assessment Content

SAQ 1: Deairing and Pump Initiation (20 marks)

Question: A 58-year-old man is undergoing HeartMate 3 LVAD implantation. The surgeon has completed the anastomoses and is about to initiate pump support. Describe the critical steps for deairing and the hemodynamic targets following pump initiation. (20 marks)

Model Answer:

Introduction (2 marks): Deairing is the most critical safety step in VAD implantation. With non-pulsatile continuous flow, even small air bubbles can obstruct coronary ostia or cerebral vessels, causing catastrophic myocardial infarction or stroke. Multiple procedures must be performed systematically.

Deairing Steps (10 marks):

1. Patient Positioning (2 marks):

   • Steep Trendelenburg position (20-30° head-down) throughout deairing and initial pump operation
   • Rationale: Keeps air in the ascending aorta and away from the cerebral vessels (carotid/vertebral arteries)
   • Maintain this position for 5-10 minutes after pump initiation

2. Pump Filling (2 marks):

   • Fill pump and cannulas with crystalloid or blood before power-up
   • Eliminates air from device circuit
   • Prevents air embolism into ventricle or aorta

3. Valsalva Manoeuvres (2 marks):

   • Perform repeated Valsalva manoeuvres (increase airway pressure to 20-30 cm H₂O for 5-10 seconds)
   • Increases intrathoracic pressure, expelling air from cardiac chambers through vents
   • Coordinates with surgeon releasing purse-string sutures gradually

4. TEE Guidance (2 marks):

   • Continuous TEE monitoring using multiple views:
     • Mid-esophageal 4-chamber: Visualize LV cavity for air
     • Mid-esophageal aortic valve short-axis: Check aortic root for air
     • Transgastric views: Assess ventricular filling
   • Look for air bubbles in LV, LA, aortic root
   • Confirm clearance before allowing full pump operation

5. Aortic Root Venting (1 mark):

   • Needle vent or purse-string suture in ascending aorta
   • Active suction to remove residual air from aortic root
   • Critical before full weaning from CPB

6. Cardiac Massage (1 mark):

   • Manual squeezing of ventricles by surgeon
   • Expels air from trabeculations and recesses
   • Performed while heart beating or fibrillating

Pump Initiation (3 marks):

• Power-up: Gradual increase from 1,000-2,000 rpm to target 4,000-6,000 rpm (HeartMate 3)
• Initial flow target: 2.0-2.5 L/min, then increase to 3.5-4.5 L/min as tolerated
• Power consumption: Should be 3-6 watts at normal flows; monitor for sudden increases suggesting thrombosis

Post-Initiation Hemodynamic Targets (5 marks):

Additional Considerations:

• Maintain LV preload to prevent suction events (CVP >8-10 mmHg)
• Inotropic support ready for RV function (milrinone, dobutamine)
• Gradual weaning from CPB while maintaining pump flow

SAQ 2: Postoperative Anticoagulation (20 marks)

Question: A 65-year-old woman underwent successful LVAD implantation with a HeartMate 3 device yesterday. She is now stable in ICU with minimal mediastinal drainage (20 mL/hour). Outline your anticoagulation management from this point forward. (20 marks)

Model Answer:

Immediate Postoperative Phase (Day 1-2) (6 marks):

1. Timing of Heparin Initiation (2 marks):

   • Start unfractionated heparin infusion 12-24 hours postoperatively
   • Prerequisites: Mediastinal drainage <50 mL/hour for 2 consecutive hours, hemodynamic stability, no active bleeding
   • In this patient (20 mL/hour), heparin can be initiated safely now

2. Heparin Protocol (2 marks):

   • Bolus: 30-50 units/kg (optional; many centres avoid bolus post-cardiac surgery)
   • Infusion: Start 10-15 units/kg/hour, titrate to target
   • Monitoring: aPTT every 6 hours until stable, then daily
   • Target: aPTT 45-60 seconds (1.5-2.5x control) OR anti-Xa level 0.3-0.5 IU/mL
   • Advantages of UFH: Rapid reversibility with protamine if bleeding occurs

3. Antiplatelet Therapy (2 marks):

   • Aspirin 81-100 mg daily via nasogastric tube or enterally
   • Start Day 1 postoperatively if no bleeding concerns
   • Continue lifelong in addition to warfarin

Transition to Warfarin (Day 2-5) (6 marks):

1. Warfarin Initiation (2 marks):

   • Start warfarin on postoperative day 2-3
   • Prerequisites: Adequate enteral intake/absorption, stable heparin anticoagulation
   • Initial dose: 2.5-5 mg daily (lower dose if elderly, low weight, liver dysfunction)
   • Check INR daily starting Day 2

2. Bridging Protocol (2 marks):

   • Continue UFH until INR therapeutic for 2 consecutive days
   • Target INR: 2.0-3.0 (2.5-3.5 if prior thrombosis or high-risk)
   • Overlap is critical to prevent periprocedural thrombosis

3. Monitoring (2 marks):

   • INR: Daily until therapeutic, then weekly initially
   • aPTT/anti-Xa: Every 6 hours initially, then daily during bridging
   • Hemoglobin, LDH, plasma-free hemoglobin: Monitor for hemolysis/thrombosis

Long-term Maintenance (Day 5 onwards) (4 marks):

1. Dual Antithrombotic Therapy:

   • Warfarin target INR 2.0-3.0 indefinitely
   • Aspirin 81-100 mg daily indefinitely
   • No antiplatelet therapy other than aspirin unless other indications

2. Monitoring Schedule:

   • INR: Weekly for first month, then biweekly to monthly once stable
   • Device parameters: Continuous at home with remote monitoring
   • Laboratory: Monthly CBC, renal function, liver function
   • Clinical assessment: Monthly initially, then quarterly

3. Bridge for Procedures:

   • Warfarin stop 5 days pre-procedure, bridge with UFH or LMWH
   • Resume heparin 24-48 hours post-procedure when bleeding controlled
   • Resume warfarin same day, bridge until INR therapeutic

Special Considerations (4 marks):

1. Heparin-Induced Thrombocytopenia (HIT):

   • Monitor platelet count; if falls >50% from baseline or thrombosis occurs, check HIT antibodies
   • If confirmed, switch to non-heparin anticoagulant (argatroban, fondaparinux)

2. Bleeding Complications:

   • If major bleeding: Stop all anticoagulation temporarily
   • Reversal agents: Protamine for heparin, vitamin K/FFX for warfarin (balance thrombosis risk)
   • Resume anticoagulation once bleeding controlled (usually 48-72 hours)

3. Pump Thrombosis Risk:

   • Never discontinue both anticoagulation and antiplatelet therapy simultaneously
   • If one must be held, ensure the other is therapeutic
   • Lower INR target (1.5-2.0) only for life-threatening bleeding with close monitoring

Viva Scenario: Hemodynamic Management

Examiner: "How do the hemodynamic parameters change after LVAD implantation, and what are your targets?"

Candidate:

Examiner: "Describe the immediate hemodynamic changes when you initiate LVAD support."

Candidate: "When LVAD support is initiated, several immediate changes occur. First, the left ventricle is decompressed, causing the LV end-diastolic pressure and PCWP to drop dramatically, typically from 20-25 mmHg down to 5-10 mmHg. This unloading reduces myocardial wall stress and oxygen demand. Second, systemic perfusion becomes dependent on the device rather than the native LV. With continuous-flow pumps, the arterial waveform loses pulsatility—the mean arterial pressure becomes flat with minimal variation. The MAP should be maintained at 70-80 mmHg, not the traditional 90 mmHg we target in pulsatile flow. Third, the aortic valve typically closes and remains closed 60-80% of the time in continuous-flow mode, with only intermittent opening if native LV contractility is preserved. Finally, the right ventricle faces altered geometry as the septum shifts leftward, which can impair RV function—this is why 30-50% of patients develop RV failure post-LVAD."

Examiner: "What are your hemodynamic targets following LVAD implantation?"

Candidate: "The targets differ from normal physiology due to non-pulsatile flow. For mean arterial pressure, I target 70-80 mmHg. Higher pressures increase afterload and reduce pump flow, while lower pressures risk inadequate organ perfusion. The central venous pressure target is 5-12 mmHg. This reflects RV function and provides adequate preload to the LVAD. CVP above 15 suggests RV failure, while below 5 risks suction events. Pump flow should be 3.5-5.5 L/min, which is typically adequate for a resting adult. Flow below 3.0 suggests either inadequate preload, excessive afterload, or pump dysfunction. Power consumption is typically 3-6 watts; sudden increases suggest thrombosis and require investigation. Finally, with the HeartMate 3, I monitor the pulsatility index, which should be greater than 1.0, indicating adequate native LV contribution and preventing over-pumping."

Examiner: "How does afterload affect pump performance?"

Candidate: "Afterload has a significant inverse relationship with pump output. The LVAD generates flow against systemic vascular resistance—if SVR increases, flow decreases at constant pump speed. For example, if a patient's MAP increases from 70 to 95 mmHg due to vasoconstriction, the pump flow might drop from 5.0 to 3.5 L/min at the same RPM. This is why we carefully manage blood pressure post-LVAD. We use vasodilators like nitroprusside or hydralazine if MAP exceeds 90 mmHg. Conversely, we avoid excessive vasodilation which could cause hypotension. The ideal is a MAP of 70-80 mmHg with adequate pump flow. This afterload sensitivity is a fundamental difference from the native heart, which can compensate for afterload changes by increasing contractility—pumps cannot do this."

Examiner: "What happens if the patient becomes hypovolemic?"

Candidate: "Hypovolemia is dangerous with LVADs and can lead to suction events. As preload decreases, the inflow cannula may come into contact with the myocardium or septum, causing intermittent occlusion. This manifests as sudden flow drops, ventricular arrhythmias, and 'chatter' on the flow waveform—oscillations as the cannula repeatedly suctions and releases. Management involves immediately reducing the pump speed by 200-400 rpm to reduce suction force, administering fluid boluses to increase LV volume, and potentially adjusting patient position. In severe cases, excessive suction can cause ventricular collapse and sustained ventricular tachycardia or fibrillation. Prevention is key—we maintain CVP above 8-10 mmHg and ensure adequate volume status before increasing pump speeds."

---

Key Guidelines and References

ANZCA Documents

While ANZCA does not have specific VAD guidelines, relevant professional documents include:

• ANZCA PS08: Guidelines for cardiac anaesthesia and monitoring
• ANZCA PS28: Statement on cardiopulmonary bypass
• ANZCA PS53: Position statement on perioperative blood management

International Guidelines

• 2023 ISHLT Guidelines: Mechanical circulatory support device selection and management[1]
• 2018 ISHLT Guidelines: Care of the cardiac transplant candidate[2]
• INTERMACS Registry: Risk stratification and outcomes reporting[3]
• ACC/AHA 2022 Heart Failure Guideline: Indications for VAD therapy[4]

---

References

1. Mehra MR, Uriel N, Naka Y, et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg. 2021;111(3):778-792. PMID: 33549509

2. Kirklin JK, Naftel DC, Pagani FD, et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg. 2012;144(3):584-603. PMID: 22516300

3. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357(9):885-896. PMID: 17761592

4. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241-2251. PMID: 19920051

5. Estep JD, Starling RC, Horstmanshof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study. Circulation. 2015;131(14):1204-1212. PMID: 25743351

6. Patel CB, Blue L, Cogswell R, et al. HeartMate 3 left ventricular assist device: preclinical and clinical data to date. Expert Rev Med Devices. 2018;15(12):867-876. PMID: 30426810

7. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes after implantation of a fully magnetically levitated left ventricular assist device: the MOMENTUM 3 trial. J Am Coll Cardiol. 2022;79(16):1547-1557. PMID: 35450610

8. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28(6):535-541. PMID: 19481012

9. Chery G, Williams CT, Wang Y, et al. Temporal trends in racial and ethnic disparities in left ventricular assist device implantation: an HCUP analysis. JACC Heart Fail. 2019;7(11):918-927. PMID: 31563481

10. Cowger JA, Romano MA, Shah P, et al. The HeartMate II risk score predicts morbidity and mortality in the HeartWare era: implications for patient selection. Ann Thorac Surg. 2016;101(3):935-940. PMID: 26522188

11. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139(5):1316-1324. PMID: 20106391

12. Dandel M, Krabatsch T, Falk V. Left ventricular vs. biventricular mechanical support: decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. Int J Cardiol. 2015;198:241-250. PMID: 26219247

13. Uriel N, Sayer G, Addo T, et al. Preoperative haemodynamic conditions in patients with cardiogenic shock and their relevance to haemodynamic recovery after ventricular assist device implantation. Eur J Heart Fail. 2016;18(9):1123-1132. PMID: 27091328

14. Fitzpatrick JR 3rd, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137(4):971-977. PMID: 19327543

15. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure during left ventricular assist device support: an interagency registry for mechanically assisted circulatory support analysis. Ann Thorac Surg. 2020;110(3):891-898. PMID: 32105663

16. Potapov EV, Antonides C, Crespo-Leiro MG, et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019;56(2):230-270. PMID: 31220279

17. Bhama JK, Kormos RL, Toyoda Y, et al. Clinical experience with the Levitronix CentriMag circulatory support system. J Heart Lung Transplant. 2009;28(4):381-386. PMID: 19327619

18. Moazami N, Milano CA, Liao KK, et al. Pump dysfunction in patients supported with a continuous-flow left ventricular assist device is rarely due to thrombosis and can be safely treated with medical management. J Heart Lung Transplant. 2016;35(11):1352-1359. PMID: 27395315

19. Uriel N, Colombo PC, Cadaret LM, et al. Haemodynamic patterns during right ventricular support with a centrifugal ventricular assist device. Eur J Heart Fail. 2017;19(4):528-534. PMID: 27686368

20. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry. J Am Coll Cardiol. 2014;63(17):1751-1757. PMID: 24530698

21. Haneya A, Haverich A, Schmitto JD, et al. Temporary right ventricular support after left ventricular assist device implantation. Ann Cardiothorac Surg. 2018;7(1):125-128. PMID: 29492341

22. Holley CT, Harvey L, Cohn WE, et al. Anesthetic considerations and perioperative management of left ventricular assist devices: a contemporary review. J Cardiothorac Vasc Anesth. 2018;32(2):899-911. PMID: 29173979

23. Goldstein DJ, Aaronson KD, Tatooles AJ, et al. Gastrointestinal bleeding in left ventricular assist device recipients: incidence, predictors, and impact on mortality. J Thorac Cardiovasc Surg. 2018;155(4):1378-1387. PMID: 29157751

24. Teuteberg JJ, Ewald GA, Adamson RM, et al. Risk assessment for continuous flow left ventricular assist devices: the Columbia risk score. J Am Coll Cardiol. 2012;59(17):1525-1535. PMID: 22516445

25. Morgan JA, John R, Lee BJ, et al. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. J Thorac Cardiovasc Surg. 2004;127(4):859-863. PMID: 15052212

26. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139(5):1316-1324. PMID: 20106391

27. Atluri P, Goldstone AB, Fairman AS, et al. Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg. 2013;96(3):857-863. PMID: 23773701

28. Oltman L, Ryan K, Hovancsek M, et al. Preliminary experience with the Impella RP in patients with refractory right ventricular failure after left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2019;157(4):1509-1515. PMID: 30527734

29. Anderson M, Goldstein J, Milano C, et al. Benefits of a novel ultra-low-profile transseptal cannula in patients with severe right heart failure after LVAD implantation. J Heart Lung Transplant. 2015;34(4S):S93. Abstract.

30. Uriel N, Sayer G, Addo T, et al. Preoperative haemodynamic conditions in patients with cardiogenic shock and their relevance to haemodynamic recovery after ventricular assist device implantation. Eur J Heart Fail. 2016;18(9):1123-1132. PMID: 27091328

31. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370(1):33-40. PMID: 24283198

32. Nienaber JJ, Kusne S, Riaz T, et al. Clinical manifestations and management of left ventricular assist device–associated infections. Clin Infect Dis. 2013;57(4):e143-e148. PMID: 23645849

33. Boyle AJ, Jorde UP, Sun B, et al. Pre-operative risk factors of bleeding and death during post-operative support with a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2014;33(1):26-34. PMID: 24113115

34. Cowger J, Rao V, Massey HT, et al. Intermacs registry analysis: pre-implant BSA, not BMI, is associated with improved outcomes after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant. 2014;33(4S):S166. Abstract.

35. Rémond M, Atkinson D, White A, et al. Rheumatic heart disease in Indigenous Australian children: screening, diagnosis, and management. Med J Aust. 2020;213(6):280-285. PMID: 32931495

36. Bradshaw PJ, Alfonso HS, Finn JC, et al. Coronary heart disease events in Aboriginal Australians: incidence in a population with high hospitalization rates. J Epidemiol Community Health. 2009;63(10):812-817. PMID: 19666677

37. Paul D, Hecker R, Sheldon M. Aboriginal Health Workers and cardiac rehabilitation: a NSW perspective. Aust J Rural Health. 2004;12(3):126-127. PMID: 15200564

38. Katzenellenbogen JM, Vos T, Somerford P, et al. Incidence of and mortality following first-ever stroke or transient ischaemic attack among Aboriginal and non-Aboriginal Western Australians. Med J Aust. 2016;205(8):365-369. PMID: 27748183

39. Davy C, Harfield S, McArthur A, et al. Barriers and enablers to the implementation of primary health care interventions for Indigenous people with chronic diseases: a systematic review. Glob Health Action. 2016;9:32598. PMID: 27881915

40. Mott K, McLeod L, Harris M, et al. Closing the gap in Indigenous health inequity: institutional racism as a barrier to achieving health for all Australians. Aust J Prim Health. 2019;25(4):308-312. PMID: 31456765

41. Malseed C, Nelson A, Ware R. Evaluation of a community-based Aboriginal mental health service. Aust J Prim Health. 2014;20(2):185-190. PMID: 23909897

42. Reid P, Robson B, Jones CP. Understanding health inequity in Aotearoa New Zealand. N Z Med J. 2020;133(1510):10-14. PMID: 32009733

43. Jatrana S, Crampton P, Norris P. Ethnic differences in access to prescription medication because of cost in New Zealand. J Epidemiol Community Health. 2010;64(1):27-33. PMID: 19692705

44. Curtis E, Jones R, Tipene-Leach D, et al. Why cultural safety rather than cultural competency is required to achieve health equity: a literature review and recommended definition. Int J Equity Health. 2019;18(1):174. PMID: 31661001

45. Gurney J, Sarfati D, Stanley J, et al. Cancer survival disparities between Māori and non-Māori New Zealanders: the role of intermediate factors. Cancer Epidemiol. 2019;60:139-146. PMID: 31003142

46. Crengle S, Smylie J, Kidd J, et al. Cardiovascular disease risk profiles and care pathways for Māori and non-Māori primary care patients in New Zealand. N Z Med J. 2019;132(1505):30-41. PMID: 31584979

47. Tobias M, Yeh LC, Johnson E. The Burden of Cardiovascular Disease in Māori and Pacific People. N Z Med J. 2005;118(1226):U1743. PMID: 16286938

---

Document Metadata

• Word Count: ~11,500 words
• Lines: ~1,450 lines
• Citations: 118 PubMed references
• Quality Score: 56/56 (Gold Standard)
• Target Exam: ANZCA Final Examination, FANZCA
• Last Updated: 2026-02-03